Asset Details
Do you wish to reserve the book?
Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV)
Do you wish to request the book?
Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV)
2014
Overview
Purpose:
We sought to characterize the natural history of vascular Ehlers–Danlos syndrome in individuals with heterozygous
COL3A1
mutations.
Methods:
We reviewed clinical records for details of vascular, bowel, and organ complications in 1,231 individuals (630 index cases and 601 relatives).
Results:
Missense and splice-site mutations accounted for more than 90% of the 572 alterations that we had identified in
COL3A1
. Median survival was 51 years but was influenced by gender (lower in men) and by the type of mutation.
Conclusion:
Although vascular Ehlers–Danlos syndrome appears to be genetically homogeneous, allelic heterogeneity is marked, and the natural history varies with gender and type of mutation in
COL3A1
. These findings indicate that when counseling families, confirmation of the presence of a
COL3A1
mutation and its nature can help evaluate the risks of complications. These data are also important ingredients in both the selection and allocation of individuals to appropriate arms in clinical trials to assess the effects of interventions.
Genet Med
16
12, 881–888.
Publisher
Nature Publishing Group US,Elsevier Limited
Subject
